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Abstract (137 words) 
 
Each year approximately 429,000 children and adolescents aged 0-19 years are expected to 
develop cancer. Five-year survival rates exceed 80% for the 45,000 children with cancer in high-
income countries (HIC), but are less than 30% for the 384,000 children in low- and middle-income 
countries (LMIC). Improved survival rates in HIC have been achieved through multidisciplinary 
care and research, with treatment regimens utilizing mostly generic medicines and optimized risk 
stratification. Children’s outcomes in LMIC can be improved by adapting effective treatments to 
local resources and clinical needs, and addressing common problems such as delayed diagnosis 
and treatment abandonment. By supporting local leaders to increase service capacity and achieve 
measurable clinical improvements, collaborative partnerships can stimulate governmental and 
nongovernmental investments. These approaches should bring the new WHO childhood cancer 




Main Text (3,724 words) 
 
In recent years, 5-year survival rates, typically equating to cure for children with cancer, have risen 
to about 80% in most high-income countries (HIC) (1-4). This progress partly reflects optimized 
use of conventional therapies (e.g., cytotoxic drugs) through better risk stratification of patients. 
For example, on the basis of molecular prognostic markers, treatments are intensified for patients 
identified as high-risk and de-escalated for patients identified as lower-risk to reduce the risks of 
immediate and long-term side effects. Expanding portfolios of new drugs that target the biological 
mechanisms driving the growth of pediatric cancers are also starting to contribute to improved 
cure rates in HIC (5).  The situation is more bleak for children with cancer in  low- and middle-
income countries (LMIC) (6). In LMIC taken as a whole, the 5-year survival rate is only about 
30%  (Table 1). Even considering only geographic sites with adequate resources to support 
population-based cancer registration, recent global data show that the 5-year survival rate for 
children can be up to 45% higher in HIC than in LMIC for acute lymphoblastic leukemia, and up 
to 51% higher for children with brain tumors (1).   
 
In 2018, the World Health Organization (WHO) set a global survival target of 60% for all children 
with cancer, with the goal of saving a million more lives by the year 2030 (7). This new WHO 
target may appear daunting, but cannot be ignored.  About 89% of the world’s children (age 0 to 
19 years) live in LMIC and they account for 95% of the mortality from cancer in this age group 
worldwide (Table 1) (4, 6). Furthermore, the incidence rates of many childhood cancers are 
increasing by about 1% per annum in many countries with population-based cancer registration 
(8).  In this Review, we aim to demonstrate that this target is tractable, building on the long-
established work of the global childhood cancer community. Success will also require new 
partnerships and increased cooperation between stakeholders, including not only health care 
professionals, but also parents, patients, civil society communities, industry, academia and 
governments (9).  
 
Global Incidence of Childhood Cancers 
The major cancer types affecting children younger than 15 years and in adolescents (aged 15-19 
years) differ from those affecting adults, which are typically epithelial in origin. The most common 
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cancers in children include acute leukemias, brain tumors, lymphomas, bone and soft tissue 
sarcomas and germ cell tumors. The typical ‘embryonal tumors’ (neuroblastoma, renal tumors and 
retinoblastoma) are confined largely to younger children whereas cancers in adolescents include 
more epithelial tumors (such as thyroid carcinoma) and melanoma. An estimated 429,000 new 
cases of childhood cancer are expected globally each year (Table 1).   Globally, the  age-
standardized reported incidence rates are 141 per million person-years (children) and 185 per 
million person-years (adolescents) (8). Age-specific incidence rates vary by geography and 
ethnicity. Notably, most of the world’s children are not covered by population-based cancer 
registries (10). Furthermore, the 170 per million incidence in HIC is double that of low-income 
countries (LIC) and lower-middle-income countries (LMIC) (Table 1, Fig. 1). However, if one 
extrapolates incidence from HIC to the sub-Saharan population, it is apparent that less than half 
the expected cases of acute leukemia, brain tumors, neuroblastoma and bone tumors are diagnosed 
(Fig. 1). In contrast, there is less of an incidence deficit for cancers that present with more obvious 
clinical symptoms such as Burkitt lymphoma, renal (Wilms) tumor and retinoblastoma (3).  Similar 
conclusions can be drawn when comparing incidence rates in India with those in Japan and Korea 
(8).  
 
Within each of the main cancer types, there are subcategories that can be treated with generic 
medicines and regimens that are readily adapted to resource-limited settings. These include Burkitt 
lymphoma, Wilms tumor, acute lymphoblastic leukaemia, Hodgkin lymphoma, certain  brain 
tumors, germ cell tumors, and low-risk or localized cases of neuroblastoma, sarcomas and 
retinoblastoma. Approximately 50% of all cancers in the 0-19 years age group would be in this 
“favorable prognosis” category if diagnosed and treated appropriately.  
 
Unfortunately, treatment failure is common in LMIC due to many factors, including failure to 
diagnose, misdiagnosis, unaffordable or abandoned treatment, toxic (treatment-related) death, and 
excess relapse  (Fig. 2) (9, 11, 12). Delayed presentation or diagnosis, drug shortages, intermittent 
adherence and treatment regimens that are of reduced intensity to facilitate tolerability also 
contribute to treatment failure. As discussed below and summarized in Fig. 3, many causes of 
treatment failure are preventable.  While children with cancer can be managed in very different 
settings in LMIC, we will use the term “cancer center” to characterize dedicated wards/units for 
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children with cancer within a hospital, as well as stand-alone hospital facilities for patients (solely 
for or including children) with cancer.   
 
The challenge of late diagnosis  
Patients whose cancer diagnosis is delayed often present with more advanced disease that is 
inherently harder to cure and necessitates more intensive therapy. Such patients often have co-
morbidities, such as malnutrition and infection and are at increased risk of tumor lysis syndrome 
and treatment-related  death (9, 13-19). When delayed diagnosis is associated with more refractory 
disease and excess relapse, this increases the costs and morbidity of treatment, and in turn increases 
treatment abandonment. As demonstrated in HIC, community-based public and professional 
awareness-raising campaigns can be effectively coupled with  diagnosis-specific referral 
guidelines; in the UK, such a national strategy reduced the median time to diagnose brain tumors 
in children from 14 weeks to just under 7 weeks (20). In Honduras, awareness materials on 
retinoblastoma, the most common eye cancer in young children, were integrated into national 
immunization platforms across health centers, and resulted in a significant decrease in the 
proportion of patients presenting with advanced retinoblastoma (21). Other resources to increase 
timely diagnosis of childhood cancer have been developed for various settings, including 
educational resources from the Pan American Health Organization, as well as locally adapted and 
international Signs and Symptoms Campaigns, with ongoing opportunities to demonstrate 
effectiveness, especially in LMIC (22-24).  
 
Reducing diagnostic failure  
Cancer diagnosis can be hampered by lack of appropriately trained workforce, imaging and 
laboratory equipment, and access to more specialized techniques such as immunohistochemistry 
and immunophenotyping that are routine in HIC pathology departments. These deficits may affect 
individual treatment centers or entire geographic regions. Even Burkitt lymphoma, which has a 
characteristic histologic appearance and is commonly diagnosed in Sub-Saharan Africa, has been 
shown to be misdiagnosed in 18-35% of cases in single and multi-centre analyses (Fig. 2) (25-27). 
Discrepancies in pathology diagnosis reached 64% in one study from Uganda that included all 
subtypes of  suspected non-Hodgkin lymphoma (26, 27). In addition to diagnostic difficulties, 
staging and risk stratification are suboptimal when patients lack access to imaging methods and 
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assays that measure prognostic biomarkers (e.g., amplification of the MYCN oncogene for 
neuroblastoma) (28). Barriers to access can be due to the unavailability of services or the inability 
of patients to pay for these services in health care systems that primarily depend on families’ out-
of-pocket contributions (29).  Strategies to facilitate earlier and more accurate cancer diagnosis in 
LMIC include the use of telemedicine with local, cross-regional or international expert groups to 
complement on-site continuing education; both clinical referral networks and professional 
networks for local input or virtual input from international experts have been successfully 
implemented in LMIC (3, 9, 30-35). An example of such long-term collaboration is outlined later 
in this Review.  
 
Targeting toxic (treatment-related) death 
Toxic death is a leading contributor to treatment failure for children with cancer in LMIC (9, 32). 
The occurrence rate can be as high as 24%-30% in higher-risk patients in the first month of therapy, 
with risk depending on the cancer type, regimen used, and supportive care available (14, 36-38). 
Appropriate supportive care especially at the start of treatment is one of the biggest challenges in 
LMIC (39). Nutritional support, management of infections, and aggressive hydration (for 
hematologic cancers and bulky tumors) to prevent tumor lysis syndrome can effectively reduce 
early toxic death (40). Resource-sensitive tools and interventions to address patients’ nutritional 
needs in LMIC have been developed as key components of supportive care (41).  In some areas of 
Africa, intestinal parasite therapy is routinely given prior to the start of chemotherapy, to help 
protect children from common infections that can become overwhelming and potentially fatal 
when the child’s immune system is weakened by malignancy as well as their treatment. Likewise, 
during treatment, other forms of antimicrobial prophylaxis and therapy have been adapted to 
localities where the incidence and types of infection differ from those in HIC (17).  To help staff 
respond quickly to infections and other causes of rapid clinical decline in children with cancer, an 
early warning system has been developed to facilitate identification, team communication and 
management of children with cancer who are deteriorating in LMIC (42). In collaboration with St. 
Jude Children’s Research Hospital, this early warning system was validated in Guatemala, where 
the system effectively reduced the number of  children who deteriorated, and decreased the need 
for patients to be transferred to the intensive care unit (43). Strategies to adapt the treatment 
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regimen to local resources and needs, with the intent to reduce toxic deaths, are further described 
below. 
 
Adapting treatment regimens in LMIC 
So-called “adapted treatment regimens” are widely used in LMIC. These are typically lower 
intensity regimens that can be associated with higher overall survival by causing fewer toxic deaths 
(44). For instance, patients with Burkitt lymphoma who have bulky disease and significant 
morbidity after initial treatment may be managed with an additional few weeks of reduced-
intensity treatment before continuing standard therapy (45). To address the challenges of bed 
shortages and other treatment delays (potentially compounding patients’ risks of not tolerating 
treatment well as their condition may worsen during the wait), some providers have incorporated 
inexpensive medicines that can be administered on an outpatient basis (e.g., hydroxyurea for 
patients with acute myeloid leukemia). Other providers, to mitigate known chemotherapy toxicity 
in settings with less available supportive care, have studied the use of reduced chemotherapy doses, 
as well as low-cost modifications to facilitate monitoring when measurement of drug levels is not 
possible (46, 47, 48Peña-Hernandez, 2019 #15297Peña-Hernandez, 2019 #15297).  Since adapted 
treatment regimens may also increase the risk of relapse due to reduced intensity treatment,  local 
data for both outcomes (toxic death rate and relapse rate) need to be continuously monitored (49, 
50). In LMIC, many factors unrelated to the treatment regimen also increase relapse risk, including 
unavailability or unaffordability of medicines, lack of adherence to treatment, and lack of 
infrastructure and support to families that enable treatment completion (Fig. 3) (35, 51-55). Ideally, 
these factors should be considered in the planning of adapted treatment regimens – for instance, 
by planning medicines that can be substituted for commonly unavailable or unaffordable 
medicines, or including funding for a clinical coordinator/patient navigator to help reinforce 
adherence to the treatment regimen. The International Paediatric Oncology Society (SIOP, 
www.SIOP-online.org) has established procedures to develop and deploy such regimens (28, 41, 
56-58).   
 
Reducing treatment abandonment 
Treatment abandonment, defined as 4 weeks or more of missed appointments during therapy, is a 
major contributor to treatment failure for children with cancer in most cancer centers in LMIC, but 
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is rare in HIC (12, 35, 38, 46, 59-63).  In some settings such as rural Zambia, abandonment rates 
approach 50%; after war or during civil unrest or natural disasters, abandonment rates increase 
sharply (64). In Côte d’Ivoire, nearly half of the children with Burkitt lymphoma abandoned 
treatment shortly after the first admission, resulting in only a 6% cure rate (Fig. 2) (65). Risk 
factors for abandonment include poverty as well as the local cost of treatment, low educational 
attainment of parents, distance from the cancer center, cancer type and, in some cases, patient 
gender; one study showed that the 12-month cumulative incidence of abandonment was  22% in 
females versus  7% in males (13). Government support matters; in a study from Kenya where more 
than 70% of children with cancer lacked health insurance at diagnosis, these children had a 3-fold 
higher risk of treatment failure (most commonly treatment abandonment) than those with 
insurance (66). To address treatment abandonment, various strategies have been deployed 
successfully.  In Central America, only 6.5% of patients with anaplastic large-cell lymphoma 
abandoned therapy, somewhat lower than the abandonment rate typically experienced with other 
tumors in the same settings, perhaps because of relatively short treatment duration (compared to 
acute lymphoblastic leukaemia) and government coverage of all chemotherapy costs (67-69). 
However, in Sierra Leone, despite shortening the duration of inpatient treatment and the provision 
of free treatment, meals and transportation, treatment abandonment persisted in rural areas, a 
finding replicated in other countries with long travel times and no established referral network (38, 
61, 70). In El Salvador, in addition to free treatment, implementation of a tracking protocol with 
community-based interventions for missed appointments successfully prevented abandonment in 
almost all patients, while in Recife, Brazil, a comprehensive social support and educational 
program reduced abandonment from 16% to 0% (38, 71). To further explore local creative 
strategies to address treatment abandonment and related topics, the global SIOP community has 
organized active working groups and launched a podcast related to these issues (59).    
 
Stimulating development of comprehensive health services for children with cancer  
Many causes of preventable treatment failure in LMIC noted above are rooted in fragile or 
insufficient health care infrastructure (including facilities) and workforce.  Childhood cancer can 
provide a lens to examine and improve the performance of health care systems more generally, 
with potential benefits beyond children with cancer. Management of childhood cancer in LMIC is 
ideally facilitated by being part of a national cancer control programme that coordinates 
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identification of priorities and resource allocation, and supports service delivery including needs 
for workforce, essential medicines and technologies, as well as information systems and policies 
(72). Additional work should be done locally to understand and address the root causes of 
diagnostic, referral and treatment delays and inform data-driven solutions to improve care 
coordination and optimize resource allocation (73). For example, improvements in the laboratory 
and pathology infrastructure and in team communication should lead to faster  diagnosis and 
response to patients’ critical electrolyte derangements or life-threatening infections – benefitting 
all patients not only children with cancer.  Similarly, prioritization of hand hygiene and isolation 
rooms for infection prevention and control should decrease morbidity and mortality for children 
with cancer and all other patients in the same hospital. The design of strategies to improve care 
should integrate the input of partners across the health system – not only clinicians, but also others 
such as policy makers responsible for budget allocations, legal and regulatory bodies overseeing 
approval of medicines, academic bodies overseeing the training and accreditation of providers, and 
civil society organizations providing support for patients and families. Successful sustained 
partnerships have stimulated the engagement of other local governmental and nongovernmental 
partners to invest in services benefiting children (73).  
 
Importantly, national policies should support the ongoing collection and analysis of local data for 
monitoring and evaluation, starting with allocating resources for infrastructure and trained 
personnel to register all newly diagnosed patients, and to document core patient outcomes such as 
survival, abandonment and relapse (71, 74, 75). Beyond increasing survival alone, coordinated 
policy efforts for children with cancer can improve patients’ quality of life and reduce suffering 
by ensuring access to morphine for pain as well as palliative care and psychosocial support (76).  
As more children survive cancer,  policies can also stipulate resources to support the distinct needs 
of children and families affected by a chronic illness like cancer, while strengthening local capacity 
to prevent, monitor, and manage late effects of treatment amongst survivors (76-78).  
 
Access to essential medicines  
An additional challenge affecting the care of children with cancer in LMIC is access to essential 
medicines. WHO has provided global guidance recommendations in the form of a Model List of 
Essential Medicines (EML) across health conditions; these include common cancers for 
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adolescents and adults since 1977, and more recently for children (up to age 12) since 2007 (79).  
Recent analyses suggest an ongoing need for implementation research within countries to facilitate 
access to the recommended medicines, particularly in resource-limited settings (54, 80).  
 
A further complexity is guaranteeing supply of high quality medicines. Here, the experience of 
Brazil with asparaginase is instructive. An essential medicine for the most common childhood 
cancer, acute lymphoblastic leukemia, asparaginase was approved by the US Food and Drug 
Administration in 1978 and recognized in the WHO EML since 1993 (79, 81). However, native 
asparaginase (derived from the bacterium Escherichia coli) has been only intermittently accessible 
in many settings (82).  In 2017, anticipating drug shortage of native asparaginase, the Ministry of 
Health in Brazil changed the national supplier to a foreign manufacturer that offered a new lower-
cost generic product (83).  Concerned by the lack of published data on this new product, 
investigators in Brazil studied the drug’s properties, and found that it was less bioactive, and 
contained contaminating proteins that increased the risk for immune-related side effects compared 
with the native asparaginase used previously (83, 84). Although the nationwide distribution of this 
new product in Brazil was halted, this drug continues to be manufactured and distributed to other 
countries around world (83). Moving forward, the WHO’s 2018 global initiative will hopefully 
engage additional partners to increase economies of scale and uphold accountability mechanisms 
for product availability and quality consistency worldwide. Lessons learned from addressing social 
and financial barriers to increase access to medicines could then also be leveraged for other critical 
technologies (7). High-quality data and research will be critical in directing how resources can be 
harnessed to reach WHO’s global goal.  
 
Science and drug development for all 
Most children with cancer in HIC are enrolled in research and multi-center clinical trials, and this 
has been described as a key factor contributing to the increased survival rates seen (2, 4, 85). 
However, there are several obstacles to further improvements in survival rates: (i) pediatric cancer 
is rare; (ii) the histologic subtypes of pediatric cancers differ substantially from those in adults; 
and (iii) the high cure rate for many pediatric cancers in HIC means that only small numbers of 
children with relapsed or refractory disease are available to enrol in early-phase trials of new drugs. 
Hence, effective drug development in pediatric oncology can benefit from engaging LMIC 
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partners. Anti-CD20 antibody therapies are one example.  Non-Hodgkin lymphoma (NHL) affects 
70,000 adults each year in the USA and several anti-CD20 antibodies are available or in 
development for CD20-positive disease (86, 87).  However, in the USA only 400 children are 
diagnosed annually with CD20-positive NHL across more than 200 pediatric oncology centers; 
fewer than 80 relapse, and even fewer relapse a second time and would be eligible for clinical trials 
for refractory mature B-cell NHL, which means that pediatric trials of novel CD20 antibodies are 
limited to a small number of eligible patients treated in a large number of centers (8). Furthermore, 
under the current paradigm, multiple pharmaceutical companies may compete for the same patient 
population to test different products with the same mechanism of action. It is not surprising that 
many drug development programs fail despite prolonged and costly efforts to meet accrual targets.  
 
To address these issues in a HIC setting, the Accelerate Platform was launched in Europe and has 
been expanded to include partners worldwide (https://www.accelerate-platform.eu/about-us/). 
Strategic aims include ensuring that drug development for children and adolescent cancers be 
based on pharmaceutical mechanism of action rather than adult indications alone, and facilitating 
international collaboration between all stakeholders - including researchers, pharma and 
governmental regulators in conjunction with influential parent/patient advocates and resourcing 
partners (88-90). While currently only European and North American centres are involved, there 
is the potential to involve well-structured cancer centres from LMIC, and indeed this may be 
essential for timely progress. Comparative analysis of survival rates between HIC and LMIC are 
limited by many factors, including different proportions of high-risk patients and environments of 
care, thus continuous research in LMIC remains vital to improve outcomes (14, 37, 91). 
Furthermore, only 11% of children with cancer live in HIC, so there is an untapped opportunity to 
help the remaining 89% of children who develop cancer in LMIC by providing them access to 
novel therapies through clinical trials, while accelerating scientific progress that can benefit all 
children (8).   
 
The “twinning program” between the pediatric oncology/hematology department at King Hussein 
Cancer Center (KHCC) in Amman (Jordan) and the neuro-oncology section at the Hospital for 
Sick Children, Toronto (Canada) exemplifies the benefit of collaborative research between 
institutions in LMIC and HIC to advance science as well as patient outcomes. Stemming from 
 11 
collaborations since 2004, monthly multidisciplinary video-teleconferences were held to discuss 
the management of KHCC patients. On average 4 to 5 patients were discussed during each 1-hour 
session. The benefits of this interaction quickly became evident for all participants (92-96). The 
group conducted a series of research projects together, and found that 17 of 44 (39%) children with 
high-grade malignant brain tumour cases at KHCC over 10 years had defective mismatch repair 
(MMR) genes, compared to less than 4% in North America (97, 98). This research led to the 
development of a larger collaborative network, the MMRD consortium, which in turn facilitated 
analyses of tumor and blood samples from individuals with MMRD-associated tumors, which are 
ultra-hypermutated and responsive to immune checkpoint inhibitors. Indeed, sustained remissions 
have been reported in MMRD patients treated with the checkpoint inhibitors nivolumab and 
ipilimumab (99, 100), and continued efforts are now warranted to initiate immunotherapy trials 
and studies of adapted treatment regimens in LMIC. Clinical trials involving LMIC partners can 
integrate local epidemiology and resource considerations into the trial design, and address new 
implementation research questions while galvanizing partnerships to sustain progress (34, 101-
104).   
 
Conclusion 
Childhood cancer demonstrates how a relatively small group of stakeholders investing in a 
relatively uncommon cluster of diseases has the potential to provide systemic benefits for science 
and health.  As we have discussed, nearly 40% of the world’s children expected to have cancer are 
undiagnosed. We need to address this problem of children not being diagnosed, while continuing 
to improve treatment for those diagnosed. We need to invest in more prospective research and 
clinical trials to improve care for children in LMIC, with the expectation that lessons learned can 
translate to global improvements. Achieving health, defined by WHO as “not merely the absence 
of disease,” requires cross-cutting investments to address underlying determinants of health and 
needs across the health system (105, 106). We advocate for health for all children with cancer, as 
summarized in the Erice Statement: “the long-term goal of the cure and care of a child with cancer 
is that he/she becomes a resilient and autonomous adult with optimal health-related quality of life, 
accepted in society at the same level as his/her peers” (107). There is no health for all unless there 
is also science for all.  
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LIC       345 83 170 28635 58650 5865 20% 10% 
LMIC 1205 86 170 103630 204850 40970 40% 20% 
UMIC 707 124 170 87668 120190 54086 62% 45% 
HIC 266 170 170 45220 45220 36176 80% 80% 
Total 2523 105 170 265153 428910 137097 52% 32% 
 
 
LIC, low-income countries; LMIC, lower-middle-income countries; UMIC, upper-middle-income 
countries; HIC, high-income countries; LMIC, low- and middle-income countries. 
 
* The expected number of cancer cases per year (170/million) is calculated by applying the mean age-
specific annual incidence rates of all high-income countries from Globocan 
(http://gco.iarc.fr/today/online-analysis-table) to the population of each country (8, 108). The incidences 
in each pediatric age cohort are 200/million among 0 to 4 year olds, 135/million among 5 to 9 year olds, 
135/million among among 10 to 14 year olds, and 211/million among 15 to 19 year olds. The United 
Nations population numbers were retrieved February 3, 2019 (109). 
** Calculated by adding all 4 World Bank income groups together. 
+ The incidence gap is defined as the percentage of patients expected to develop cancer each year divided 
by the mean of the incidence reported in high-income countries. Some variation is expected based on 
epidemiologic variation; whereas, lack of diagnosis is a likely cause of gaps that exceed 2 standard 








This map shows the percentage of children expected to develop cancer each year who are diagnosed. The incidence ratio is calculated 
by dividing the number of cases reported in a country by the number expected if incidences were the same as those in high-income 
countries, where non-diagnosis is rare, and the incidence deficit is the incidence ratio subtracted from 100%. An incidence ratio of 





Fig. 2 Causes of treatment failure for children with cancer by World Bank income categories for all children with cancer and 
selected Burkitt lymphoma studies in low-, middle-, and high-income countries 
HIC, high-income countries; UMIC, upper-middle-income countries; LMIC, lower-middle-income countries; LIC, low-income 
countries.  Although the causes of treatment failure in HIC differ from those in UMIC, LMIC, and LIC (left section of figure), a 
variety of published studies of Burkitt lymphoma in each World Bank income group illustrate that even within the same World Bank 
group, the relative contribution of each cause of treatment failure differs in different settings, even for the same cancer. In the Burkitt 
lymphoma studies, non-diagnosis, misdiagnosis, and no treatment are estimates, since these are not reported in the clinical trials 
themselves. Studies specifically addressing misdiagnosis in sub-Saharan African have found rates as high as 18-35% (26). Used with 





Fig. 3 Cause-specific interventions to reduce treatment failure for children with cancer in low- and middle-income countries 
 
 
Each cause of treatment failure has contributing sub-causes and proven prevention and mitigation strategies. QI, quality improvement.  
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